ARTICLE | Product Development
2021 Predictions: a BioCentury survey
BioCentury’s SAB weighs in on what to expect in biotech in 2021 (See link at end to participate)
December 18, 2020 10:27 PM UTC
While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one vaccination at a time.
BioCentury surveyed members of its scientific advisory board and select other KOLs from December 2 to 8 about their expectations for innovation, clinical readouts, COVID-19 and the financing and dealmaking landscape in 2021. The respondents were a cohort of 18 biopharma C-suite executives, pharma R&D heads and investors based in the U.S., Europe and China. Responses were anonymous...